Researchers from the Broad Institute, Mass General, Stanford, and elsewhere are investigating why patients with South Asian ...

The company will use the proceeds to test its gene therapy XC001 in two Phase II studies involving patients with cardiovascular disease.

New investor Jeito Capital, a global leading private equity fund, led the Series B financing round which also included existing institutional investors EQT, Fountain Healthcare Partners, and Lumira ...

In a large-animal model study, researchers have found that heart attack recovery is aided by injection of heart muscle cell spheroids derived from human induced pluripotent stem cells, or hiPSCs, that ...

After a heart attack, humans lose millions of heart muscle cells that cannot regrow, often leading to heart failure where the ...

HYDERABAD: Health will become more personalised and accessible, with innovations across nutrition, paediatrics, dermatology, ...

A study published in Human Gene Therapy has involved the generation of a human monoclonal antibody (mAb) directed against ...

The company is trying to develop a one-time treatment for forms of heart disease that afflict more than 1 million people in ...

The new name draws from the company’s nearly two decades of work in ryanodine receptor (RyR) biology, which it has used to ...

Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...

Cell and Gene Therapy Tools and Reagents (2024-2029) - Trends, Strategies, and ESG Innovations Shaping Growth BOSTON, Jan. 7, 2025 /PRNewswire/ ...